Literature DB >> 7270599

Detrusor instability syndrome: the use of bladder retraining drills with and without anticholinergics.

J A Fantl, W G Hurt, L J Dunn.   

Abstract

Ninety-two (24.6%) of 374 patients referred to our gynecologic urology unit were found to have instability of the detrusor muscle with no recognizable associated pathologic conditions: idiopathic detrusor instability. Thirty-nine (42.4%) of these 92 patients demonstrated the instability only after detrusor activation maneuvers such as coughing, heel bouncing, or positional changes. The cure rate among patients with both "spontaneous" and "provoked" contractions of the detrusor muscle was comparable to the cure rate among those whose bladder contractions were apparent only after detrusor activation maneuvers (p greater than 0.9). The success rate of bladder retraining drills (BRD) as the sole mode of therapy was not significantly different from that observed with BRD combined with anticholinergics (p greater than 0.6).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7270599     DOI: 10.1016/0002-9378(81)90079-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms.

Authors:  Diane K Newman; Diane Borello-France; Vivian W Sung
Journal:  Neurourol Urodyn       Date:  2017-05-02       Impact factor: 2.696

Review 2.  Cognitive components of behavioral therapy for overactive bladder: a systematic review.

Authors:  Becca Reisch; Rebekah Das; Brynne Gardner; Katie Overton
Journal:  Int Urogynecol J       Date:  2021-02-20       Impact factor: 2.894

3.  A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder.

Authors:  M B Chancellor; F Kianifard; E Beamer; L Mongay; U Ebinger; G Hicks; A Delconte
Journal:  Int J Clin Pract       Date:  2008-04       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.